Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PRESS RELEASE : SHOP APOTHEKE EUROPE: Growth in Q2 temporarily decelerated to 7.3%. Preliminary sales grew by 14.9% during the first six months of 2021.

07/06/2021 | 01:33am EDT
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Development of Sales 
SHOP APOTHEKE EUROPE: Growth in Q2 temporarily decelerated to 7.3%. Preliminary sales grew by 14.9% during the first 
six months of 2021. 
2021-07-06 / 07:30 
The issuer is solely responsible for the content of this announcement. 
SHOP APOTHEKE EUROPE: Growth in Q2 temporarily decelerated to 7.3%. Preliminary sales grew by 14.9% during the first 
six months of 2021. 
  . Temporarily reduced logistics capacity due to the ongoing move to the new facility and a tight labour market in Q2. 
  . Full-year 2021 guidance of growing around 20% and earnings guidance on adjusted EBITDA margin of 2.3 - 2.8% has 
    become challenging. 
  . Strong customer demand continued in all of countries. 
  . SHOP APOTHEKE EUROPE is ready for e-Rx and Gematik started the roll-out in a test environment last week. 
  . Strong progress on strategic initiatives: Same-day delivery service SHOP APOTHEKE NOW! is available in all major 
    German metropolitan areas ahead of schedule. 
Sevenum, 6 July 2021. SHOP APOTHEKE EUROPE, active in seven European countries, has increased sales for H1 2021 by 
14.9% to EUR 534 million. On a quarterly basis, sales rose by 7.3% to EUR 250 million. The number of active customers 
increased in Q2 alone by 0.3 million to well above 7 million. 
CEO Stefan Feltens: "The execution of our strategic initiatives as well as customer demand in all countries we serve 
continued to develop strongly in Q2. The testing period for e-Rx in Germany has gone live as scheduled on 1 July 2021, 
and our same-day delivery service SHOP APOTHEKE NOW! is already available to more than 20 million people in 13 
metropolitan areas across Germany including Berlin, Hamburg and Munich. However, we had to slow down our growth this 
quarter, which will impact our earnings in Q2. Staff numbers failed to maintain pace to fully cope with increasing 
customer demand both in Q2 and at the start of Q3. Additionally, the ramp-up to the next level of automation takes more 
time than we aimed for and temporarily operating two logistics facilities in parallel is complex." 
In the DACH segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE's Q2 sales grew by 3.8% to EUR 198 million 
compared to previous year's 190 million. H1 sales increased by 9.5% to EUR 428 million after EUR 391 million in 2020. 
Declining Rx sales were offset by double digit growth in the non-Rx categories. 
In the International segment (Belgium, France, Italy, the Netherlands), SHOP APOTHEKE EUROPE increased its sales in the 
second quarter of 2021 by 23.0% to EUR 52 million compared to EUR 42 million in Q2 2020. H1 sales increased by 43.4% to 
EUR 105 million after EUR 74 million in 2020. 
For the full-year 2021, the Management Board of SHOP APOTHEKE EUROPE has an earnings guidance of organically driven 
sales growth of around 20% or more and an adjusted EBITDA margin in the range of a positive 2.3% - 2.8% (2020: 2.2%). 
This guidance for 2021 has become challenging due to the current lower than anticipated logistics capacity; whether an 
update will be needed depends on the developments of the coming weeks. 
All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release the full interim report for 
the second quarter of 2021 on 5 August 2021. Definitions of non-IFRS terms can be found in the Glossary of the Annual 
Report 2020 (pages 146 and 147). 
SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, 
Austria, France, Belgium, Italy, the Netherlands and Switzerland. 
Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Warsaw, 
Milan, Paris and Tongeren, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original 
products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by 
high quality natural food and health products, low carb products and sports nutrition. Currently, more than 7 million 
active customers trust SHOP APOTHEKE EUROPE. 
Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides 
comprehensive pharmaceutical consulting services. 
In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further 
improve the customer experience with focus on disease-specific digital medication management services following the 
acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself 
from a pure online retailer into a truly customer-centric e-pharmacy platform. 
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) 
since 2016 and has been part of the MDAX stock index since September 2020. 
Trade and popular media: 
Sven Schirmer 
Tel: +49 221 99 53 44 31 
Email: presse@shop-apotheke.com 
Financial media: 
Bettina Fries 
Tel: +49 211 75 80 779 
Email: presse@shop-apotheke.com 
Investor relations: 
Carmen Herkenrath 
Tel.: +31 77 850 6109 
Email: carmen.herkenrath@shop-apotheke.com 
Thomas Schnorrenberg 
Mobile: +49 151 465 31317 
Email: presse@shop-apotheke.com 
2021-07-06 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
              Dirk Hartogweg 14 
              5928 LV Venlo 
Phone:        0800 - 200 800 300 
Fax:          0800 - 90 70 90 20 
E-mail:       carmen.herkenrath@shop-apotheke.com 
Internet:     www.shop-apotheke-europe.com 
ISIN:         NL0012044747, DE000A19Y072 
WKN:          A2AR94, A19Y07 
Indices:      MDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1215468 
End of News   DGAP News Service 

1215468 2021-07-06

Image link: 

(END) Dow Jones Newswires

July 06, 2021 01:32 ET (05:32 GMT)

09/22SHOP APOTHEKE EUROPE NV : Berenberg reiterates its Buy rating
09/20SHOP APOTHEKE EUROPE N.V.(XTRA : SAE) added to Germany SDAX (Total Return) Index
09/17SHOP APOTHEKE EUROPE N.V.(XTRA : SAE) dropped from Germany MDAX Index (Performance)
09/16SHOP APOTHEKE EUROPE : Move to Next Generation Logistics Centre Completed.
09/16PRESS RELEASE : SHOP APOTHEKE EUROPE: Move to Next Generation Logistics Centre Completed.
09/14SHOP APOTHEKE EUROPE NV : Kepler Cheuvreux keeps a Sell rating
09/01SHOP APOTHEKE EUROPE NV : Buy rating from Jefferies
08/09SHOP APOTHEKE EUROPE NV : Buy rating from Baader Bank
08/06SHOP APOTHEKE EUROPE NV : Deutsche Bank gives a Buy rating
More news
Analyst Recommendations on SHOP APOTHEKE EUROPE N.V.
More recommendations
Sales 2021 1 106 M 1 296 M 1 296 M
Net income 2021 -30,1 M -35,3 M -35,3 M
Net Debt 2021 24,6 M 28,8 M 28,8 M
P/E ratio 2021 -81,2x
Yield 2021 -
Capitalization 2 479 M 2 903 M 2 905 M
EV / Sales 2021 2,26x
EV / Sales 2022 1,74x
Nbr of Employees 1 211
Free-Float 97,8%
Duration : Period :
Shop Apotheke Europe N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOP APOTHEKE EUROPE N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 11
Last Close Price 137,00 €
Average target price 193,45 €
Spread / Average Target 41,2%
EPS Revisions
Managers and Directors
Stefan Feltens Chief Executive Officer
Jasper Eenhorst Chief Financial Officer
Bj÷rn H. S÷der Chairman-Supervisory Board
Marc Fischer Chief Information Officer
Theresa Holler Chief Operating Officer
Sector and Competitors